Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: A systematic review of the literature and a survey of Canadian gastroenterologists

Canadian Journal of Gastroenterology

Volumn 15, Issue 1, 2001, Pages 21-28

  Wallace, T M ^a   van Zanten, S J O V ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

6 mercaptopurine; Azathioprine; Inflammtory bowel disease

Indexed keywords

AZATHIOPRINE; LIVER ENZYME; MERCAPTOPURINE; PANCREAS ENZYME;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD CELL COUNT; CANADA; CANCER RISK; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG USE; ENTERITIS; GASTROENTEROLOGY; HUMAN; LANGUAGE; LEUKEMIA; LIVER TOXICITY; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PANCREATITIS; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; STANDARD;

EID: 0035119378     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/518192     Document Type: Article

References (49)

1. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study
2. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis
3. The long term outcome of ulcerative colitis treated with 6-mercaptopurine
4. Azathioprine: State of the art in inflammatory bowel disease
5. The clinical pharmacology of 6-mercaptopurine
6. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine
7. Azathioprine therapy
8. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
9. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease
10. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity
11. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
12. A controlled double blind study of azathioprine in the management of Crohn's disease
13. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis
14. Azathioprine in inflammatory bowel disease, a safe alternative?
15. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
16. Thiopurine methyltransferase activity in American white subjects and black subjects
17. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism
18. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients
19. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients
20. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
21. Molecular diagnosis of thiopurine s-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
22. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
23. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
24. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
25. Intracellular thiopurine nucleotides and azathioprine myelotoxicity in organ transplant patients
26. Azathioprine-related pancreatitis in patients with Crohn's disease
27. Rapid development of pancreatitis following reuse of 6-mercaptopurine
28. Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity
29. Azathioprine and the liver: Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans
30. Hepatotoxicity of 6-mercaptopurine in Crohn's disease
31. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
32. Allergic reactions to 6-mercaptopurine-during treatment of inflammatory bowel disease
33. Hypersensitivity reaction to azathioprine
34. Chemical immunosuppression and human cancer
35. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
36. The use of azathioprine and 6-mercaptopurine (6-MP) as immunosuppressive therapy in inflammatory bowel disease and its role in the etiology of lymphocytic lymphoma
37. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease
38. Development of lymphoma in patients with Crohn disease
39. Lymphoma in inflammatory bowel disease: A study of 9 cases
40. The role of azathioprine in the management of ulcerative colitis
41. Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine
42. Genotypic analysis of thiopurine s-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
43. Azathioprine for maintenance of remission in Crohn's disease benefits outweigh the risk of lymphoma
44. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
45. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
46. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease
47. National cooperative Crohn's disease study: Adverse reactions to study drugs